277 related articles for article (PubMed ID: 31327258)
41. Risk of New-Onset Dyslipidemia After Laparoscopic Adrenalectomy in Patients with Primary Aldosteronism.
Kaga M; Utsumi T; Tanaka T; Kono T; Nagano H; Kawamura K; Kamiya N; Imamoto T; Nihei N; Naya Y; Suzuki H; Ichikawa T
World J Surg; 2015 Dec; 39(12):2935-40. PubMed ID: 26296835
[TBL] [Abstract][Full Text] [Related]
42. Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Lales G; Mitas C; Doumas M
Curr Pharm Des; 2018; 24(46):5508-5516. PubMed ID: 30854950
[TBL] [Abstract][Full Text] [Related]
43. Benefits of Surgical Over Medical Treatment for Unilateral Primary Aldosteronism.
Ahmed S; Hundemer GL
Front Endocrinol (Lausanne); 2022; 13():861581. PubMed ID: 35557845
[TBL] [Abstract][Full Text] [Related]
44. Postoperative renal impairment and longitudinal change in renal function after adrenalectomy in patients with Cushing's syndrome.
Nakamura Y; Yokoyama M; Yoshida S; Tanaka H; Kijima T; Ishioka J; Matsuoka Y; Saito K; Minami I; Yoshimoto T; Naito S; Ogawa Y; Yamada T; Uchida S; Fujii Y
Int J Urol; 2020 May; 27(5):395-400. PubMed ID: 32157752
[TBL] [Abstract][Full Text] [Related]
45. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases.
Morales E; Millet VG; Rojas-Rivera J; Huerta A; Gutiérrez E; Gutiérrez-Solís E; Egido J; Praga M
Nephrol Dial Transplant; 2013 Feb; 28(2):405-12. PubMed ID: 23222416
[TBL] [Abstract][Full Text] [Related]
46. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.
Funder JW; Carey RM; Mantero F; Murad MH; Reincke M; Shibata H; Stowasser M; Young WF
J Clin Endocrinol Metab; 2016 May; 101(5):1889-916. PubMed ID: 26934393
[TBL] [Abstract][Full Text] [Related]
47. Primary Aldosteronism in Chronic Kidney Disease: Blood Pressure Control and Kidney and Cardiovascular Outcomes After Surgical Versus Medical Management.
Cohen DL; Wachtel H; Vaidya A; Hundemer GL; Tezuka Y; Davio A; Turcu AF; Cohen JB
Hypertension; 2023 Oct; 80(10):2187-2195. PubMed ID: 37593884
[TBL] [Abstract][Full Text] [Related]
48. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.
Catena C; Colussi G; Lapenna R; Nadalini E; Chiuch A; Gianfagna P; Sechi LA
Hypertension; 2007 Nov; 50(5):911-8. PubMed ID: 17893375
[TBL] [Abstract][Full Text] [Related]
49. Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.
Wu VC; Chan CK; Chueh JS; Chen YM; Lin YH; Chang CC; Lin PC; Chung SD;
J Am Heart Assoc; 2023 Feb; 12(4):e028146. PubMed ID: 36789834
[TBL] [Abstract][Full Text] [Related]
50. Renal Resistive Index Predicts Postoperative Blood Pressure Outcome in Primary Aldosteronism.
Iwakura Y; Ito S; Morimoto R; Kudo M; Ono Y; Nezu M; Takase K; Seiji K; Ishidoya S; Arai Y; Funamizu Y; Miki T; Nakamura Y; Sasano H; Satoh F
Hypertension; 2016 Mar; 67(3):654-60. PubMed ID: 26865201
[TBL] [Abstract][Full Text] [Related]
51. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.
Morimoto S; Ichihara A
Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201
[TBL] [Abstract][Full Text] [Related]
52. Time-Dependent Risk of Atrial Fibrillation in Patients With Primary Aldosteronism After Medical or Surgical Treatment Initiation.
Kim KJ; Hong N; Yu MH; Lee H; Lee S; Lim JS; Rhee Y
Hypertension; 2021 Jun; 77(6):1964-1973. PubMed ID: 33866798
[TBL] [Abstract][Full Text] [Related]
53. Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma.
Amar L; Lorthioir A; Azizi M; Plouin PF
Eur J Endocrinol; 2015 Mar; 172(3):R125-9. PubMed ID: 25315875
[TBL] [Abstract][Full Text] [Related]
54. Intrarenal hemodynamics in primary aldosteronism before and after treatment.
Sechi LA; Di Fabio A; Bazzocchi M; Uzzau A; Catena C
J Clin Endocrinol Metab; 2009 Apr; 94(4):1191-7. PubMed ID: 19141581
[TBL] [Abstract][Full Text] [Related]
55. Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?
Sechi LA; Colussi GL; Novello M; Uzzau A; Catena C
Horm Metab Res; 2015 Dec; 47(13):1000-6. PubMed ID: 26667803
[TBL] [Abstract][Full Text] [Related]
56. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma.
; Wu VC; Chueh SC; Chang HW; Lin LY; Liu KL; Lin YH; Ho YL; Lin WC; Wang SM; Huang KH; Hung KY; Kao TW; Lin SL; Yen RF; Chen YM; Hsieh BS; Wu KD
Am J Kidney Dis; 2009 Oct; 54(4):665-73. PubMed ID: 19628318
[TBL] [Abstract][Full Text] [Related]
57. Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism.
Lin YF; Peng KY; Chang CH; Hu YH; Wu VC; Chung SD;
Endocrinol Metab (Seoul); 2020 Dec; 35(4):838-846. PubMed ID: 33261310
[TBL] [Abstract][Full Text] [Related]
58. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies.
Marzano L; Colussi G; Sechi LA; Catena C
Am J Hypertens; 2015 Mar; 28(3):312-8. PubMed ID: 25336498
[TBL] [Abstract][Full Text] [Related]
59. Larger ascending aorta in primary aldosteronism: a 3-year prospective evaluation of adrenalectomy vs. medical treatment.
Zavatta G; Di Dalmazi G; Pizzi C; Bracchetti G; Mosconi C; Balacchi C; Pagotto U; Vicennati V
Endocrine; 2019 Mar; 63(3):470-475. PubMed ID: 30430353
[TBL] [Abstract][Full Text] [Related]
60. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy.
Fischer E; Hanslik G; Pallauf A; Degenhart C; Linsenmaier U; Beuschlein F; Bidlingmaier M; Mussack T; Ladurner R; Hallfeldt K; Quinkler M; Reincke M
J Clin Endocrinol Metab; 2012 Nov; 97(11):3965-73. PubMed ID: 22893716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
